Tirzepatide，CAS：2023788-19-2，MW：4813.53，MF：C225H348N48O68

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-Eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 
     Tirzepatide, a weekly double agonist of glucose dependent insulin stimulating peptide (GIP, also known as gastric inhibitory peptide) receptor and pancreatic peptide-1 (GLP-1) receptor developed by Lilly. In May 2022, Tirzepatide, as a "first in class" drug, was approved by the US FDA for marketing. It is the first new generation diabetes drug launched in the past decade. Tilposide defeated Smeglutide in phase III clinical head-on trials and is bound to become a strong competitor in the field of hypoglycemic and weight loss.